Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells

British Journal of Haematology

Volumn 106, Issue 1, 1999, Pages 86-91

  Locke, Vicki L ^a   Davey, Ross A ^b   Davey, Mary W ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Etoposide; Idarubicin; Multidrug resistance; Sensitization; Topoisomerase

Indexed keywords

AMSACRINE; ETOPOSIDE; IDARUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; HUMANS; IDARUBICIN; K562 CELLS; LEUKEMIA;

EID: 0032864463     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01494.x     Document Type: Article

References (26)

1. Berman, E. (1993) A review of idarubicin in acute leukemia. Oncology, 7, 91-104.
2. Bishop, J.P. (1997) The treatment of adult acute myeloid leukemia. Seminars in Oncology, 24, 57-69.
3. Chen, M. & Beck, W.T. (1995) DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncology Research, 7, 103-111.
4. Davey, M.W., Hargrave, R.M. & Davey, R.A. (1996) Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. Leukemia Research, 20, 657-664.
5. Davey, R.A., Su, G.M., Hargrave, R.M., Harvie, R.M., Baguley, B.C. & Davey, M.W. (1997) The potential of N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemotherapy and Pharmacology, 39, 424-430.
6. Davies, S.M., Davies, S.L., Harris, A.L. & Hickson, L.D. (1989). Isolation of two Chinese hamster ovary mutants hypersensitive to topoisomerase II inhibitors and cross-resistant to peroxides. Cancer Research, 49, 4526-4530.
7. Deeley, R.G. & Cole, S.P.C. (1997) Function, evolution and structure of multidrug resistance protein (MRP). Seminars in Cancer Biology, 8, 193-204.
8. Friedman, H.S., Dolan, M.E., Kaufmann, S.H., Colvin, O.M., Griffith, O.W., Moschel, R.C., Schold, S.C., Bigner, D.D. & Aliosman, F. (1994) Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosourcas and topotecan. Cancer Research, 54, 3487-3493.
9. Gottesman, M.M. & Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Reviews of Biochemistry, 62, 385-427.
10. Grech, K.V., Davey, R.A. & Davey, M.W. (1998) The relationship between modulation of MDR and glutathione in MRP-over-expressing human leukemia cells. Biochemical Pharmacology, 55, 1283-1289.
11. Hargrave, R., Davey, M., Davey, R. & Kidman, A. (1995) Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anticancer Drugs, 6, 432-437.
12. Harker, W.G., Slade, D.L., Parr, R.L., Feldhoff, P.W., Sullivan, D.M. & Holguin, M.H. (1996) Alterations in the topoisomerase H-alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II-beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Research, 55, 1707-1716.
13. Mankhetkorn, S., Dubru, F., Hesschenbrouck, J., Fiallo, M. & Garniersuillerot, A. (1996) Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Molecular Pharmacology, 49, 532-539.
14. Marks, D.C., Belov, L., Davey, M.W., Davey, R.A. & Kidman, A.D. (1992) The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leukemia Research, 16, 1165-1173.
15. Marks, D.C., Davey, M.W., Davey, R.A. & Kidman, A.D. (1993) Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line. British Journal of Haematology, 84, 83-89.
16. Mirski, S.E.L., Gerlach, J.H., Cummings, H.J., Zirngibl, R., Greer, P.A. & Cole, S.P.C. (1997) Bipartite nuclear localization signals in the C terminus of human topoisomerase II-alpha. Experimental Cell Research, 237, 452-455.
17. Mulder, H.S., Dekker, H., Pinedo, H.M. & Lankelma, J. (1995) The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Biochemical Pharmacology, 50, 967-974.
18. Nussler, V., Gieseler, F., Zwierzina, H., Gullis, E., Pelkafleischer, R., Diem, H., Abenhardt, W., Schmitt, R., Langenmayer, I., Wohlrab, A., Kolb, H.J. & Williams, W. (1997) Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression. Annals of Hematology, 74, 57-64.
19. Ritke, M.K., Roberts, D., Allan, W.P., Raymond, J., Bergoltz, V.V. & Yalowich, J.C. (1994) Altered stability of etoposide-induced topoisomerase II DNA complexes in resistant human leukaemia K562 cells. British Journal of Cancer, 69, 687-697.
20. Ross, D., Doyle, A., Cuddy, D. & Gao, Y. (1997) HL60 cells selected with idarubicin (IDA) display multidrug resistance (MDR) associated with an altered topoisomerase II, but not with enhanced transport-mediated cellular defenses. Proceedings of the American Association for Cancer Research, 38, 19.
21. Stadheim, C., Heaton, R., Glinsmann-Gibson, B., Grogan, T. & List, A. (1998) Idarubicin (IDA) selection results in MDR1-mediated multidrug resistance in the K562 human myeloid leukemia cell line. Proceedings of the American Association for Cancer Research, 39, 215.
22. Tan, K.B., Mattern, M.R., Eng, W.-Q., McCabe, F.L. & Johnson, R.K. (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlations with resistance to topoisomerase inhibitors. Journal of the National Cancer Institute, 81, 1732-1735.
23. Toffoli, G., Simone, F., Gigante, M. & Boiocchi, M. (1994) Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochemical Pharmacology, 48, 1871-1881.
24. Tomida, A., Naito, M. & Tsuruo, T. (1995) Acute induction of adriamycin-resistance in human colon carcinoma HT-29 cells exposed to a sublethal dose of adriamycin. Japanese Journal of Cancer Research, 86, 224-232.
25. Van Der Graaf, W.T., De Vries, E.G., Timmer Bosseha, H., Meersma, G.J., Mesander, G., Vellenga, F., & Mulder, N.H. (1994) Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. Cancer Research, 54, 5368-5373.
26. Yamazaki, K., Isobe, H., Hanada, T., Betsuyaku, T., Hasegawa, A., Hizawa, N., Ogura, S. & Kawakami, Y. (1997) Topoisomerase II-alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 39, 192-198.